Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of rimegepant for preventive treatment of pediatric migraine in Japan
jRCT2031240036Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Rimegepant with Placebo (2 arms). Primary endpoint: Change from baseline in mean number of migraine days per month in adolescents with episodic migraine over 12 weeks. Started Jun 2024; status: recruiting.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on jRCT2031240036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240036.